Franklin M. Berger - 18 Mar 2022 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Director
Signature
/s/ Marc Belsky, Attorney-in-fact
Issuer symbol
KZR
Transactions as of
18 Mar 2022
Net transactions value
+$1,299,800
Form type
4
Filing time
22 Mar 2022, 17:45:52 UTC
Previous filing
23 Sep 2021
Next filing
19 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KZR Common Stock Purchase $239,400 +15,000 +1.9% $15.96 825,691 18 Mar 2022 Direct F1
transaction KZR Common Stock Purchase $765,000 +45,000 +5.4% $17.00 870,691 18 Mar 2022 Direct F2
transaction KZR Common Stock Purchase $295,400 +20,000 +2.3% $14.77 890,691 21 Mar 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.47 to $16.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3).
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.885 to $17.01 inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.44 to $15.00 inclusive.